Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 351 clinical trials
Novel Gamma-Delta (γδ)T Cell Therapy for Treatment of Patients With Newly Diagnosed Glioblastoma (DRI)

This study is being conducted to find out if the safety and tolerability of an experimental cell therapy is safe to administer to patients with a newly diagnosed glioblastoma multiforme (GBM) in

Accepts healthy volunteers
  • 0 views
  • 23 Mar, 2022
  • 1 location
A Study of Itacitinib for the Prevention of Cytokine Release Syndrome Induced by Immune Effector Cell Therapy

"The purpose of this study is to assess the safety and efficacy of oral administration of itacitinib for the prevention of cytokine release syndrome (CRS) in male or female participants aged 12 years or older and who are planning to receive an approved immune effector cell (IEC) therapy for hematologic …

  • 2 views
  • 06 Jun, 2022
  • 9 locations
Exploratory Study of Novel MSLN CAR-T Cell Therapy in Patients With MSLN-positive Advanced Refractory Solid Tumors

This is a single-arm, open-label, exploratory clinical study to evaluate the safety and efficacy of novel Mesothelin CAR-T in patients with Mesothelin-positive advanced refractory solid tumors.

  • 0 views
  • 07 Oct, 2022
  • 1 location
Safety and Efficacy of ALLO-605 an Anti-BCMA Allogeneic CAR T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma

The purpose of the ALLO-605-201 study is to assess the safety, efficacy, and cell kinetics of ALLO605 in adults with relapsed or refractory multiple myeloma after a lymphodepletion regimen comprising fludarabine, cyclophosphamide, and ALLO-647.

  • 0 views
  • 22 Mar, 2022
  • 4 locations
A Study of CD19 Targeted CAR T Cell Therapy in Adult Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukaemia (ALL)

This is a Phase Ib/II study to evaluate the safety and efficacy of autologous T cells engineered with a chimeric antigen receptor (CAR) targeting CD19 in adult patients with relapsed or refractory B cell acute lymphoblastic leukemia (ALL).

  • 1 views
  • 07 Oct, 2022
  • 33 locations
A Phase 2 Single-Center Open Label Study of Autologous Adoptive Cell Therapy Following a Reduced Intensity Non-myeloablative Lymphodepleting Induction Regimen in Metastatic Urothelial Carcinoma Patients

An autologous, Adoptive Cell Therapy Following a Reduced Intensity, Non-myeloablative, Lymphodepleting Induction Regimen in Metastatic Urothelial Carcinoma Patients.

  • 0 views
  • 17 Feb, 2021
  • 1 location
Anti-CD33 CAR NK Cells in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia

CAR technology has been used in T cell therapy and gets great success in treating hematological diseases. Following models of CAR T cells, CAR NK cell therapy has been one hot point. For myeloid

remission
ejection fraction
hematologic disorder
cell transplantation
flow cytometry
  • 0 views
  • 25 Mar, 2022
  • 1 location
  • 47 views
  • 28 Oct, 2022
  • 17 locations
Master Protocol for the Phase 1 Study of Cell Therapies in Multiple Myeloma

Master protocol for cell therapy, Phase 1 proof-of-concept studies in relapsed and refractory multiple myeloma and includes long-term safety follow-up.

  • 0 views
  • 04 Oct, 2022
  • 2 locations
CAR-T Cells in Treating Patients With Relapsed or Refractory Multiple Myeloma

This study is aimed to evaluate the safety, feasibility and efficacy of CAR-T cell therapy in the treatment of relapsed or refractory multiple myeloma

  • 0 views
  • 27 Jan, 2021
  • 1 location